Literature DB >> 7353082

Intravascular haemolysis and renal failure caused by intermittent rifampicin treatment.

A Criel, R L Verwilghen.   

Abstract

Rifampicin is a widely used anti-tuberculous drug. Administered daily, only minimal side-effects occur. With intermittent therapy and, as happened in the present case, when the drug is administered after an interruption of treatment, severe adverse reactions [5] (thrombocytopenia, renal failure, and haemolysis) may occur.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7353082     DOI： 10.1007/bf01013697

Source DB:  PubMed          Journal:  Blut        ISSN： 0006-5242


  6 in total

1.  Hong Kong Treatment Services-Royal Postgraduate Medical School-British Medical Research Council Co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. The detection of rifampicin-dependent antibodies.

Authors:  S Worlledge
Journal:  Scand J Respir Dis Suppl       Date:  1973

2.  [Acute renal failure after rifampicin (author's transl)].

Authors:  H J Germann; G F Hoppe-Seyler; W H Boesken
Journal:  Dtsch Med Wochenschr       Date:  1974-07-05       Impact factor: 0.628

3.  Potentially serious side effects of high-dose twice-weekly rifampicin.

Authors:  G Poole; P Stradling; S Worlledge
Journal:  Br Med J       Date:  1971-08-07

4.  [Hemolytic crisis due to rifampicin].

Authors:  W Hasse; H D Pohle; F Warnecke; K Wiek
Journal:  Prax Pneumol       Date:  1971-08

Review 5.  Acute renal failure after rifampicin: a case report and survey of the literature.

Authors:  R Nessi; G L Bonoldi; B Redaelli; G di Filippo
Journal:  Nephron       Date:  1976       Impact factor: 2.847

6.  [Hemolytic crisis and acute kidney failure from rifampicin].

Authors:  D Conen; A Blumberg; S Weber; H Schubothe
Journal:  Schweiz Med Wochenschr       Date:  1979-04-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.